Baker Bros. Advisors LP Infla Rx N.V. Transaction History

Baker Bros. Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$2.72 - $4.04 $375,468 - $557,681	-138,040 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$3.62 - $6.34 $2.6 Million - $4.55 Million	-718,188 Reduced 83.88%	138,040 $538,000
Q4 2020 Feb 16, 2021	SELL	$3.82 - $5.32 $578,084 - $805,080	-151,331 Reduced 15.02%	856,228 $4.31 Million
Q3 2020 Nov 16, 2020	SELL	$3.7 - $5.47 $188,685 - $278,948	-50,996 Reduced 4.82%	1,007,559 $4.29 Million
Q2 2020 Aug 14, 2020	SELL	$4.59 - $8.96 $3.3 Million - $6.45 Million	-719,860 Reduced 40.48%	1,058,555 $4.86 Million
Q3 2019 Nov 14, 2019	BUY	$2.47 - $3.51 $4.39 Million - $6.24 Million	1,778,415 New	1,778,415 $4.39 Million
Q2 2019 Aug 14, 2019	SELL	$3.06 - $51.61 $547,700 - $9.24 Million	-178,987 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$29.34 - $35.0 $2.34 Million - $2.79 Million	-79,837 Reduced 30.85%	178,987 $6.14 Million
Q2 2018 Aug 14, 2018	BUY	$27.33 - $41.46 $1.61 Million - $2.44 Million	58,824 Added 29.41%	258,824 $8.35 Million
Q4 2017 Feb 14, 2018	BUY	$14.55 - $23.99 $2.91 Million - $4.8 Million	200,000	200,000 $4.19 Million

12.9M

19.3K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $99M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.